RxSight’s blended fair value estimate has edged down to US$10.17 from US$10.39, reflecting a modest recalibration in the latest round of research updates. Analysts are largely sticking with neutral ...

RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was ...

Remember, when we look back a year ago, Q1 2025 was our best LDD volume quarter and our second-best LAL unit volume quarter, ...

Analysts' ratings for RxSight (NASDAQ:RXST) over the last quarter vary from bullish to bearish, as provided by 3 analysts. The table below provides a concise overview of recent ratings by analysts, ...

RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments “Based on our fourth quarter results, ...

Q4 2025 earnings call recap: sales, LAL/LDD trends, 2026 revenue & margin guidance, risks and catalysts—read the key takeaways now.

In the last three months, 11 analysts have published ratings on RxSight (NASDAQ:RXST), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings ...

Within the last quarter, RxSight (NASDAQ:RXST) has observed the following analyst ratings: These 4 analysts have an average price target of $31.0 versus the current price of RxSight at $28.84, ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action ...

ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, ...